Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 623

1.

Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.

Lin P, Wen DY, Dang YW, He Y, Yang H, Chen G.

Cell Physiol Biochem. 2018;47(3):925-947. doi: 10.1159/000490135. Epub 2018 May 24.

2.

BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.

Lian G, Li L, Shi Y, Jing C, Liu J, Guo X, Zhang Q, Dai T, Ye F, Wang Y, Chen M.

Int J Oncol. 2018 Mar;52(3):804-814. doi: 10.3892/ijo.2018.4255. Epub 2018 Jan 25.

3.

SUMOylation Promotes Nuclear Import and Stabilization of Polo-like Kinase 1 to Support Its Mitotic Function.

Wen D, Wu J, Wang L, Fu Z.

Cell Rep. 2017 Nov 21;21(8):2147-2159. doi: 10.1016/j.celrep.2017.10.085.

4.

Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway.

Ma X, Wang L, Huang, Li Y, Yang D, Li T, Li F, Sun L, Wei H, He K, Yu F, Zhao D, Hu L, Xing S, Liu Z, Li K, Guo J, Yang Z, Pan X, Li A, Shi Y, Wang J, Gao P, Zhang H.

Nat Commun. 2017 Nov 15;8(1):1506. doi: 10.1038/s41467-017-01647-5.

5.

PLK1 Activation in Late G2 Sets Up Commitment to Mitosis.

Gheghiani L, Loew D, Lombard B, Mansfeld J, Gavet O.

Cell Rep. 2017 Jun 6;19(10):2060-2073. doi: 10.1016/j.celrep.2017.05.031.

6.

Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.

Diab A, Foca A, Fusil F, Lahlali T, Jalaguier P, Amirache F, N'Guyen L, Isorce N, Cosset FL, Zoulim F, Andrisani O, Durantel D.

Hepatology. 2017 Dec;66(6):1750-1765. doi: 10.1002/hep.29236. Epub 2017 Nov 6.

7.

Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines.

Zhu L, Xing S, Zhang L, Yu JM, Lin C, Yang WJ.

Oncotarget. 2017 Jun 6;8(23):37633-37645. doi: 10.18632/oncotarget.16839.

8.

Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.

Shin SB, Woo SU, Lee YJ, Yim H.

Anticancer Res. 2017 Mar;37(3):1177-1183.

PMID:
28314279
9.

PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.

Pezuk JA, Brassesco MS, de Oliveira RS, Machado HR, Neder L, Scrideli CA, Tone LG.

Childs Nerv Syst. 2017 Apr;33(4):609-615. doi: 10.1007/s00381-017-3366-5. Epub 2017 Mar 10.

PMID:
28283778
10.

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.

Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q.

Br J Cancer. 2017 Apr 11;116(8):1027-1036. doi: 10.1038/bjc.2017.55. Epub 2017 Mar 7.

11.

Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.

Gutteridge RE, Singh CK, Ndiaye MA, Ahmad N.

Cancer Lett. 2017 May 28;394:13-21. doi: 10.1016/j.canlet.2017.02.013. Epub 2017 Feb 22.

12.

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.

Koncar RF, Chu Z, Romick-Rosendale LE, Wells SI, Chan TA, Qi X, Bahassi EM.

Oncotarget. 2017 Feb 28;8(9):15827-15837. doi: 10.18632/oncotarget.15015.

13.

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.

Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.

Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268.

14.

Mitotic phosphotyrosine network analysis reveals that tyrosine phosphorylation regulates Polo-like kinase 1 (PLK1).

Caron D, Byrne DP, Thebault P, Soulet D, Landry CR, Eyers PA, Elowe S.

Sci Signal. 2016 Dec 13;9(458):rs14.

PMID:
27965426
15.

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N.

Cancer Lett. 2017 Jan 28;385:179-187. doi: 10.1016/j.canlet.2016.10.025. Epub 2016 Oct 25.

16.

Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy.

Cebrián A, Gómez Del Pulgar T, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Marín-Arango JP, Caramés C, Vega-Bravo R, Rodríguez-Remírez M, Manzarbeitia F, García-Foncillas J.

Pathol Res Pract. 2016 Dec;212(12):1133-1137. doi: 10.1016/j.prp.2016.09.012. Epub 2016 Sep 22.

PMID:
27712975
17.

Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.

Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.

Clin Exp Ophthalmol. 2017 Apr;45(3):288-296. doi: 10.1111/ceo.12838. Epub 2016 Nov 10.

PMID:
27647547
18.

Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.

Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R.

BMC Cancer. 2016 Aug 18;16:647. doi: 10.1186/s12885-016-2690-6.

19.

Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis.

Otsu H, Iimori M, Ando K, Saeki H, Aishima S, Oda Y, Morita M, Matsuo K, Kitao H, Oki E, Maehara Y.

Oncology. 2016;91(1):31-40. doi: 10.1159/000445952. Epub 2016 Jun 2.

PMID:
27245623
20.

Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.

Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X, Yu C.

Oncol Rep. 2016 Jul;36(1):49-56. doi: 10.3892/or.2016.4820. Epub 2016 May 18.

Supplemental Content

Support Center